EFG Asset Management North America Corp. Takes $1.98 Million Position in Icon Plc $ICLR

EFG Asset Management North America Corp. acquired a new stake in Icon Plc (NASDAQ:ICLR) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,336 shares of the medical research company’s stock, valued at approximately $1,984,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. Private Trust Co. NA grew its stake in shares of Icon by 200.0% in the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after acquiring an additional 94 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in Icon during the 2nd quarter worth $48,000. LRI Investments LLC purchased a new stake in Icon during the 2nd quarter worth about $49,000. Blue Trust Inc. raised its position in Icon by 44.0% in the 2nd quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 120 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB boosted its stake in shares of Icon by 153.4% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock valued at $58,000 after buying an additional 201 shares during the period. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $187.97 on Wednesday. Icon Plc has a 12 month low of $125.10 and a 12 month high of $211.00. The firm has a market capitalization of $15.18 billion, a P/E ratio of 25.44, a P/E/G ratio of 3.96 and a beta of 1.26. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The company’s fifty day moving average price is $182.54 and its 200 day moving average price is $176.05.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ICLR. BMO Capital Markets assumed coverage on Icon in a research report on Thursday, November 13th. They set a “market perform” rating and a $175.00 price objective for the company. Zacks Research upgraded shares of Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 25th. UBS Group set a $220.00 price objective on shares of Icon in a report on Friday, October 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Icon in a research note on Monday, December 29th. Finally, Barclays raised their price target on Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat, Icon has an average rating of “Hold” and a consensus target price of $200.60.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.